Phase 1 Site Director

• Lead a purpose-built private Phase 1 clinical trials unit positioned for significant growth within the New Zealand market.
• Join a rapidly expanding trans-Tasman clinical research organisation at a pivotal stage of transformation, integration and commercial growth.
• Shape a high-performing, sponsor-preferred site delivering complex and First-in-Human studies across a rapidly growing pipeline.

THE OPPORTUNITY

Momentum Clinical Research is the largest trans-Tasman provider of clinical research services, operating across Australia and New Zealand with significant growth ambitions across the Asia-Pacific region. Recently unified under the Momentum brand, the organisation is entering an exciting phase of operational alignment, scalability and market expansion.

The Takapuna Phase 1 Unit is a strategically important, purpose-built private Phase 1 facility established to support the growing demand for complex early phase and First-in-Human studies within New Zealand. Already demonstrating strong commercial performance and increasing sponsor interest, the site is now entering its next stage of operational maturity and growth.

This newly created Site Director role has been established to strengthen operational leadership, sponsor confidence and commercial performance as the organisation continues to scale its Phase 1 capability and market presence.

THE ROLE

Reporting to the Chief Operating Officer, the Phase 1 Site Director will lead the operational, commercial and clinical performance of the Takapuna Phase 1 Unit. The role combines executive leadership with hands-on oversight across complex Phase 1 trial delivery, sponsor and CRO engagement, workforce capability, quality and governance, and commercial growth.

Leading a multidisciplinary workforce, the successful candidate will drive operational excellence across participant safety, protocol execution, audit readiness, workforce utilisation and sponsor satisfaction, while supporting the continued growth and positioning of the site within the market.

THE CANDIDATE

The successful candidate will bring significant experience within Phase 1 or early phase clinical research environments, including exposure to complex and First-in-Human studies.

You will be a commercially astute and operationally credible leader with strong people leadership capability, the ability to build trusted sponsor relationships and experience leading high-performing teams through growth, transformation and operational change. Candidates may come from nursing, medical, health sciences or broader clinical research leadership backgrounds, however demonstrated Phase 1 operational leadership experience will be essential.

For a confidential discussion, please get in touch with:

David
National Manager, New Zealand
​M. +64 (0)21 0239 2211 | E. dprice@hardygroupintl.com

HOW TO APPLY

The closing date for applications is Thursday, 25th June 2026

The reference number to include in your application is H26_5519